Hepatitis C virus envelope glycoprotein (HCV E1/E2 glycoprotein)

The Hepatitis C virus envelope glycoprotein refers to the viral proteins E1 and E2 embedded in the lipid membrane of hepatitis C virus particles. E1 (positions 192-383 on the HCV polyprotein) and E2 (384-746) form a noncovalent, heavily glycosylated heterodimer that is critical for viral attachment, entry, fusion, and immune evasion. These proteins mediate recognition and binding to host cell receptors (including CD81) and facilitate the fusion of viral and cellular membranes. E2 is the major target for neutralizing antibodies, with a distinctive hypervariable region (HVR1) conferring immune escape and sequence heterogeneity. E1 is also implicated in the fusion process and viral assembly. Both are focus areas for antiviral and vaccine research due to their key role in the HCV lifecycle. Human therapeutics include direct-acting antivirals and monoclonal antibodies aiming to block E1/E2 functions. The high sequence diversity, glycosylation, and rapid mutation rate of these glycoproteins present major challenges to therapy and vaccine development.

Other names

E1 glycoproteinE2 glycoproteinHCV envelope proteinHCV E1/E2Hepacivirus envelope glycoprotein

Blocking viral entry: Drugs/antibodies prevent E1/E2 from binding to host cell receptors (e.g., CD81), thus stopping fusion and infection. Neutralization: Antibodies bind E2 and neutralize infectivity. Interference with glycosylation/structure: Some antivirals/antibodies disrupt heterodimer formation or folding.